Net Loss Per Share The following table sets forth the computation of basic and diluted loss per share: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | | | | | (in thousands, except share and per share data) | | 2021 | | 2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Numerator (both basic and diluted): | | | | | | | | | | | | | | | | | | Loss from continuing operations | | $ | (33,475) | | | $ | (136,429) | | | | | | | | | | | | | | | Loss from discontinued operations, net of tax | | (3,797) | | | (8,452) | | | | | | | | | | | | | | | Net loss available to common stockholders | | $ | (37,272) | | | $ | (144,881) | | | | | | | | | | | | | | | Denominator: | | | | | | | | | | | | | | | | | | Weighted-average shares used for basic and diluted earnings per share (a) | | 24,900 | | | 24,914 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Loss from continuing operations per share, basic and diluted: | | $ | (1.35) | | | $ | (5.48) | | | | | | | | | | | | | | | Loss from discontinued operations per share, basic and diluted: | | (0.15) | | | (0.34) | | | | | | | | | | | | | | | Net loss per share, basic and diluted: | | $ | (1.50) | | | $ | (5.82) | | | | | | | | | | | | | | |
(a) The Company has issued potentially dilutive instruments. However, the Company did not include these instruments in its calculation of diluted loss per share, because to include them would be anti-dilutive. The following table sets forth weighted average shares outstanding of potentially dilutive instruments: | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | (in thousands) | | 2021 | | 2020 | | | | | | | | | | Series A Preferred stock | | 118,805 | | | 28,722 | | | | | | Warrants | | 2,067 | | | 2,067 | | | | | | Unvested restricted stock units | | 159 | | | 420 | | | | | | Stock options | | 194 | | | 227 | | | | | | Total | | 121,225 | | | 31,436 | | | | | |
|